SCHEMBL210677

SCHEMBL210677

c1ccc2c(c1)NCC21CCNCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.45
KDM1A O60341 1/20 0.42
HTR2A P28223 4/20 0.41
DRD2 P14416 1/20 0.41
SLC6A2 P23975 1/20 0.41
HTR2C P28335 1/20 0.41
SLC6A4 P31645 1/20 0.41
TNKS O95271 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
OPRM1 P35372 3/20 0.40
OPRL1 P41146 1/20 0.40
AVPR1A P37288 1/20 0.38
SIGMAR1 Q99720 2/20 0.38
KCNH2 Q12809 1/20 0.36
HDAC1 Q13547 1/20 0.36
TSHR P16473 2/20 0.34
USP2 O75604 2/20 0.33
CYP2D6 P10635 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29384112 1.00 BACE1 (0.45) BACE1KDM1AHTR2ADRD2SLC6A2
Iodide SCHEMBL9047078 0.98 BACE1 (0.44) BACE1KDM1AHTR2ADRD2SLC6A2
Hydrochloric Acid SCHEMBL8063249 0.98 BACE1 (0.44) BACE1KDM1AHTR2ADRD2SLC6A2
Hydrochloric Acid SCHEMBL6543309 0.98 BACE1 (0.44) BACE1KDM1AHTR2ADRD2SLC6A2
SCHEMBL762104 0.91 BACE1 (0.47) BACE1KDM1AHTR2ADRD2SLC6A2
SCHEMBL29387315 0.91 BACE1 (0.47) BACE1KDM1AHTR2ADRD2SLC6A2
SCHEMBL11095419 0.91 BACE1 (0.47) BACE1KDM1AHTR2ADRD2SLC6A2
Hydrochloric Acid SCHEMBL25279576 0.89 BACE1 (0.46) BACE1KDM1AHTR2ADRD2SLC6A2
SCHEMBL1012828 0.88 TNKS (0.44) BACE1KDM1AHTR2ADRD2SLC6A2
SCHEMBL29479467 0.88 TNKS (0.44) BACE1KDM1AHTR2ADRD2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4320125-A1 PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2024-02-14 EP claimed
EP-2370423-A1 METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF Glaxo Group Limited (GB) 2011-10-05 EP claimed
US-20110230660-A1 METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF Method for Preparing a Spiroindoline 2011-09-22 US claimed
WO-2010065704-A1 METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF GLAXO GROUP LIMITED (GB) 2010-06-10 WO claimed
US-20040220223-A1 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2004-11-04 US claimed
US-20020049329-A1 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2002-04-25 US claimed
US-6291672-B1 FOR THE PREPARATION OF DRUGS USEFUL IN THERAPY OF PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, HYPERTENSION SANOFI-SYNTHELABO (FR) 2001-09-18 US claimed
EP-0702681-A1 SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS MERCK & CO. INC. (US) 1996-03-27 EP claimed
WO-1994029309-A1 SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS MERCK & CO., INC. (US) 1994-12-22 WO claimed
US-12466829-B2 Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2025-11-11 US disclosed
US-20250195483-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2025-06-19 US disclosed
EP-4320125-A1 PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2024-02-14 EP disclosed
CN-116113698-A TRPML modulators 卡斯玛治疗公司 2023-05-12 CN disclosed
US-20230126662-A1 SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-04-27 US disclosed
US-4307235-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1981-12-22 US disclosed
US-4307235-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1981-12-22 US disclosed
US-4307235-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1981-12-22 US disclosed
US-4209625-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1980-06-24 US disclosed
US-4209625-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1980-06-24 US disclosed
US-4209625-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1980-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466829-B2 Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC2R, MC1R, MC3R BACE1 4444/4885KDM1A 4163/4885HTR2A 25/4885
US-20040220223-A1 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them TACR2, BDKRB2, ACKR3 BACE1 4721/4885KDM1A 3153/4885HTR2A 798/4885
US-20250195483-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, PNLIP, SAAL1 BACE1 1860/4885KDM1A 4604/4885HTR2A 3660/4885
US-20020049329-A1 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them TACR2, BDKRB2, ACKR3 BACE1 4721/4885KDM1A 3153/4885HTR2A 798/4885
US-20110230660-A1 METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF CCR2, CXCR4, CXCR2 BACE1 4460/4885KDM1A 4474/4885HTR2A 616/4885
US-20230126662-A1 SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC2R, MC1R, MC3R BACE1 4444/4885KDM1A 4163/4885HTR2A 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.